Cargando…

L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial

Antimicrobial peptides represent an important component of the innate immune defenses of living organisms, including humans. They are broad-spectrum surface-acting agents secreted by the epithelial cells of the body in response to infection. Recently, L-isoleucine and its analogues have been found t...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, N.H., Raqib, R., Ashraf, H., Qadri, F., Ahmed, S., Zasloff, M., Agerberth, B., Salam, M.A., Gyr, N., Meier, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Centre for Diarrhoeal Disease Research, Bangladesh 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131118/
https://www.ncbi.nlm.nih.gov/pubmed/21766553
_version_ 1782207689651126272
author Alam, N.H.
Raqib, R.
Ashraf, H.
Qadri, F.
Ahmed, S.
Zasloff, M.
Agerberth, B.
Salam, M.A.
Gyr, N.
Meier, R.
author_facet Alam, N.H.
Raqib, R.
Ashraf, H.
Qadri, F.
Ahmed, S.
Zasloff, M.
Agerberth, B.
Salam, M.A.
Gyr, N.
Meier, R.
author_sort Alam, N.H.
collection PubMed
description Antimicrobial peptides represent an important component of the innate immune defenses of living organisms, including humans. They are broad-spectrum surface-acting agents secreted by the epithelial cells of the body in response to infection. Recently, L-isoleucine and its analogues have been found to induce antimicrobial peptides. The objectives of the study were to examine if addition of L-isoleucine to oral rehydration salts (ORS) solution would reduce stool output and/or duration of acute diarrhoea in children and induce antimicrobial peptides in intestine. This double-blind randomized controlled trial was conducted at the Dhaka Hospital of ICDDR,B. Fifty male children, aged 6-36 months, with acute diarrhoea and some dehydration, attending the hospital, were included in the study. Twenty-five children received L-isoleucine (2 g/L)-added ORS (study), and 25 received ORS without L-isoleucine (control). Stool weight, ORS intake, and duration of diarrhoea were the primary outcomes. There was a trend in reduction in mean±standard deviation (SD) daily stool output (g) of children in the L-isoleucine group from day 2 but it was significant on day 3 (388±261 vs 653±446; the difference between mean [95% confidence interval (CI) (-)265 (−509, −20); p=0.035]. Although the cumulative stool output from day 1 to day 3 reduced by 26% in the isoleucine group, it was not significant. Also, there was a trend in reduction in the mean±SD intake of ORS solution (mL) in the L-isoleucine group but it was significant only on day 1 (410±169 vs 564±301), the difference between mean (95% CI) (-)154 (-288, −18); p=0.04. The duration (hours) of diarrhoea was similar in both the groups. A gradual increase in stool concentrations of ß-defensin 2 and 3 was noted but they were not significantly different between the groups. L-isoleucine-supplemented ORS might be beneficial in reducing stool output and ORS intake in children with acute watery diarrhoea. A further study is warranted to substantiate the therapeutic effect of L-isoleucine.
format Online
Article
Text
id pubmed-3131118
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher International Centre for Diarrhoeal Disease Research, Bangladesh
record_format MEDLINE/PubMed
spelling pubmed-31311182011-08-16 L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial Alam, N.H. Raqib, R. Ashraf, H. Qadri, F. Ahmed, S. Zasloff, M. Agerberth, B. Salam, M.A. Gyr, N. Meier, R. J Health Popul Nutr Original Papers Antimicrobial peptides represent an important component of the innate immune defenses of living organisms, including humans. They are broad-spectrum surface-acting agents secreted by the epithelial cells of the body in response to infection. Recently, L-isoleucine and its analogues have been found to induce antimicrobial peptides. The objectives of the study were to examine if addition of L-isoleucine to oral rehydration salts (ORS) solution would reduce stool output and/or duration of acute diarrhoea in children and induce antimicrobial peptides in intestine. This double-blind randomized controlled trial was conducted at the Dhaka Hospital of ICDDR,B. Fifty male children, aged 6-36 months, with acute diarrhoea and some dehydration, attending the hospital, were included in the study. Twenty-five children received L-isoleucine (2 g/L)-added ORS (study), and 25 received ORS without L-isoleucine (control). Stool weight, ORS intake, and duration of diarrhoea were the primary outcomes. There was a trend in reduction in mean±standard deviation (SD) daily stool output (g) of children in the L-isoleucine group from day 2 but it was significant on day 3 (388±261 vs 653±446; the difference between mean [95% confidence interval (CI) (-)265 (−509, −20); p=0.035]. Although the cumulative stool output from day 1 to day 3 reduced by 26% in the isoleucine group, it was not significant. Also, there was a trend in reduction in the mean±SD intake of ORS solution (mL) in the L-isoleucine group but it was significant only on day 1 (410±169 vs 564±301), the difference between mean (95% CI) (-)154 (-288, −18); p=0.04. The duration (hours) of diarrhoea was similar in both the groups. A gradual increase in stool concentrations of ß-defensin 2 and 3 was noted but they were not significantly different between the groups. L-isoleucine-supplemented ORS might be beneficial in reducing stool output and ORS intake in children with acute watery diarrhoea. A further study is warranted to substantiate the therapeutic effect of L-isoleucine. International Centre for Diarrhoeal Disease Research, Bangladesh 2011-06 /pmc/articles/PMC3131118/ /pubmed/21766553 Text en © INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Alam, N.H.
Raqib, R.
Ashraf, H.
Qadri, F.
Ahmed, S.
Zasloff, M.
Agerberth, B.
Salam, M.A.
Gyr, N.
Meier, R.
L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial
title L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial
title_full L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial
title_fullStr L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial
title_full_unstemmed L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial
title_short L-isoleucine-supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children: A Randomized Controlled Trial
title_sort l-isoleucine-supplemented oral rehydration solution in the treatment of acute diarrhoea in children: a randomized controlled trial
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131118/
https://www.ncbi.nlm.nih.gov/pubmed/21766553
work_keys_str_mv AT alamnh lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial
AT raqibr lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial
AT ashrafh lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial
AT qadrif lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial
AT ahmeds lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial
AT zasloffm lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial
AT agerberthb lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial
AT salamma lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial
AT gyrn lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial
AT meierr lisoleucinesupplementedoralrehydrationsolutioninthetreatmentofacutediarrhoeainchildrenarandomizedcontrolledtrial